Associated Papers
Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity.
Barliana MI et al.
Frontiers in Genetics, 2023
UGT2B7 gene polymorphism and linkage disequilibrium in pediatric epileptic patients and their influence on sodium valproate monotherapy: A cohort study.
Adiga S et al.
Frontiers in Pharmacology, 2022
UGT1A6 and UGT2B7 Gene Polymorphism and its Effect in Pediatric Epileptic Patients on Sodium Valproate Monotherapy.
Nandith PB et al.
Indian Journal of Pediatrics, 2021
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I et al.
British Journal of Clinical Pharmacology, 2018
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Du Z et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016
Effect of UGT2B7 genetic variants on serum valproic acid concentration.
Ma H et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences, 2013
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
Picard N et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases.
Mackenzie PI et al.
Toxicology and Applied Pharmacology, 2005
Select a paper to view details